Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

B-AVD (Brentuximab vedotin-Dacarbazine-Doxorubicin-Vinblastine)

Description: Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-DACARBAZINE-DOXORUBICIN-VINBLASTINE (B- AVD) Regimen • Lymphoma – Brentuximab vedotin - Dacarbazine-Doxorubicin-Vinbl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/B-AVD-Brentuximab-vedotin-Dacarbazine-Doxorubicin-Vinblastine.pdf

Incidental meningioma - patient information

Description: This factsheet explains what an incidental meningioma is, what this diagnosis means for you, and what follow-up care you will
Url: /Media/UHS-website-2019/Patientinformation/Brain-and-spine/Incidental-meningioma-3719-PIL.pdf

BV-CHP Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Ver1

Description: Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE (BV-CHP) Regimen • Lymphoma – Brentuximab vedotin-cyclophosphamide-doxorubic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BV-CHP-Brentuximab-vedotin-cyclophosphamide-doxorubicin-prednisolone.pdf

Rituximab (weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (weekly) Regimen Lymphoma – Rituximab (weekly) Indication CD20 positive indolent non Hodgkin’s lymphoma. Toxicity Drug Rituxumab Advers
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-weekly.pdf

Rituximab (3 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (3 Weekly) Regimen Lymphoma – Rituximab (3 weekly) Indication Non Hodgkin’s Lymphoma in combination with chemotherapy Toxicity Drug Rituxumab Ad
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-3-weekly.pdf

O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Regimen (O-CVP) • NHL – O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Indication • O
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine.pdf

O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine (O-CHOP) Regimen • NHL – O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-PrednisoloneV
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine.pdf

Bendamustine-Obinutuzumab

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Bendamustine-Obinutuzumab Regimen • NHL – Bendamustine-Obinutuzumab Indication • Obinutuzumab in combination with bendamustine followed by obinut
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Obinutuzumab.pdf

HSCTRituximab_100mg-7day

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT RITUXIMAB 100mg (Weekly) Regimen • HSCT Allograft - Rituximab (7 day-100mg) Indications • EBV reactivation, PTLD and immune medi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTRituximab-100mg-7day.pdf

IdelalisibRituximab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia (CLL) Idelalisib-Rituximab Regimen • CLL – Idelalisib-Rituximab Indication • Chronic lymphocytic leukaemia in adul
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/IdelalisibRituximab.pdf

11 to 20 of 127

Previous 1 2 3 4 5 … Next